determines the number of low-density lipoprotein (LDL) receptors in the body. These receptors then regulate how much LDL cholesterol (sometimes called “bad” cholesterol) enters the bloodstream.

Office coffee doesn't pretend to be the crème de la crème of brews, but new research suggests your common room’s cup of joe ...

A cholesterol receptor protein called LDLR appears to be a key driver of neurotoxicity in sporadic ALS, per new research ...

Once processed by LPL, the VLDL becomes a VLDL remnant. The majority of the VLDL remnants are taken up by the liver via the LDL receptor, and the remaining remnant particles become IDL ...

By Vijay Kumar Malesu Study deciphers the molecular handshake between LDL receptors and apoB100, shedding light on cholesterol metabolism and its role in cardiovascular disease. Study: Structure of ...

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ...

Alzheimer’s disease (AD) is often recognized by its well-known symptoms—memory loss, confusion, and cognitive decline. But ...

Familial hypercholesterolemia results from gene mutations approximately halving the number of functional LDL receptors in heterozygotes and a greater lack in homozygotes. Reduced receptor-mediated ...

LDL is often called “bad” cholesterol because when it accumulates in the blood, it can form plaque in the arteries, a condition known as atherosclerosis. This is a major risk factor for heart disease.

AstraZeneca’s AZD0780 is an investigational oral medication that was developed to lower low-density lipoprotein cholesterol ... does not affect the PCSK9-LDL receptor (LDLR) interaction.